T 0500/16 of 30.09.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T050016.20210930
- Date of decision
- 30 September 2021
- Case number
- T 0500/16
- Petition for review of
- -
- Application number
- 10701175.1
- IPC class
- A61K 31/47A61P 35/00C07D 215/227
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER
- Applicant name
- Exelixis, Inc.
- Opponent name
- Gallafent, Alison
Actavis Group PTC ehf
Ladendorf, Oliver - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 12(2)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)Rules of procedure of the Boards of Appeal Art 25(2)
- Keywords
- Inventive step
Novelty
Sufficiency of disclosure
Late-filed facts - Catchword
- -
- Cited cases
- G 0003/14T 0184/00T 1329/04T 0710/05T 0608/07T 0777/08T 0415/11T 1744/14T 1875/15T 0184/16T 0488/16T 1083/16T 1684/16T 0405/17
- Citing cases
- T 1107/22
Order
For these reasons it is decided that:
The appeals are dismissed.